Clinical trials
Phase 3 Hyperglycemia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 11 |
| 2009 | 6 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 3 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Terminated | 5 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sanofi | 8 |
| Takeda | 4 |
| AstraZeneca | 3 |
| Baylor College of Medicine | 2 |
| Medical University of Vienna | 2 |
| Asan Medical Center | 1 |
| Boehringer Ingelheim | 1 |
| Boston Medical Center | 1 |
| Centre Hospitalier of Chartres | 1 |
| Eli Lilly and Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperglycemia | 49 |
| Diabetes Mellitus, Type 2 | 18 |
| Diabetes Mellitus | 11 |
| Hypoglycemia | 9 |
| Insulin Resistance | 7 |
| Diabetes Mellitus, Type 1 | 4 |
| Metabolic Syndrome | 4 |
| Critical Illness | 3 |
| Glucose Intolerance | 3 |
| Obesity | 3 |
Trials
Showing 76 to 49 of 49. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.